FDA Approves New ADHD Drug Simtriyo With Novel Mechanism, Experts Urge Caution

The U.S. Food and Drug Administration (FDA) recently approved Simtriyo (centanafadine), a new medication for attention deficit hyperactivity disorder (ADHD) treatment in children aged six and older, adolescents, and adults. Unlike most existing ADHD drugs that target dopamine and norepinephrine, Simtriyo also affects serotonin, making it the first approved drug in the NDSRI class.

The FDA's approval was based on four phase 3 clinical trials demonstrating significant symptom reduction compared to placebo, with some patients showing improvement within the first week. However, common side effects were reported, including decreased appetite, abdominal pain, nausea, headaches, and rash in children and adolescents, and insomnia, dry mouth, and diarrhea in adults.

Despite the excitement, ADHD specialists caution that regulatory approval does not guarantee superiority over established treatments with decades of clinical experience. They emphasize the need for long-term data and broader clinical use to fully assess Simtriyo's efficacy, safety, and impact on quality of life. Currently, Simtriyo is not approved for use in Israel, as it must undergo local regulatory review before marketing.

Experts view the introduction of Simtriyo positively as it expands treatment options, especially for patients who do not respond well to existing medications or experience adverse effects. Nonetheless, they advise against rushing to label it a "miracle drug," underscoring the importance of individualized treatment plans that combine medical diagnosis, monitoring, and potentially behavioral or educational interventions. Decisions to switch to new therapies should rely on solid medical evidence and accumulated clinical experience rather than novelty alone.